Covidien Reports Third-Quarter Results




    Pro forma diluted loss per share from continuing operations was ($2.23);
excluding specified items, pro forma adjusted diluted earnings per share from
continuing operations was $0.67

    PEMBROKE, BERMUDA, August 9 /CNW/ - Covidien Ltd. (NYSE:   COV; BSX: COV)
today reported results for the third quarter of fiscal 2007 (April - June
2007), its first quarterly report following the separation from Tyco
International on June 29, 2007. Third-quarter net sales increased 5% from a
year ago to $2.6 billion, led by the Medical Devices and Pharmaceutical
Products business segments. Sales growth was driven by higher volume and new
products. Favorable foreign exchange contributed 2 percentage points to the
sales increase. Strong double-digit sales growth was posted internationally,
led by Europe and Other Americas, primarily Latin America.

    Gross margin of 48% in the quarter was up more than a full percentage
point from that of the prior year. Favorable product mix and cost savings
resulting from strategic sourcing initiatives, manufacturing efficiencies and
operational excellence activities were partially offset by the negative impact
of higher raw materials and transportation costs.

    The quarter included considerably higher Selling, general and
administrative expenses. The growth in these expenses was attributable to a
planned increase in selling and marketing investments and higher quarterly
administrative expenses, primarily due to increases in compensation expense,
as well as costs to separate from Tyco International. Research and Development
(R&D) spending was also above a year ago.

    For the third quarter, the Company reported an operating loss of $730
million versus operating income of $557 million a year ago. The third-quarter
2007 operating loss included a $1.2 billion charge for Covidien's portion of
the Tyco International class action settlement, a $30 million charge for
in-process research and development related to the Sorbx technology
acquisition and a $5 million restructuring charge. Excluding these three
specified items, third-quarter operating income would have been $512 million,
representing 19.9% of sales.

    The third-quarter effective tax rate was negative 19.9%. The tax rate for
the quarter includes two items for which no tax benefit was realized: the
charges related to the allocated net class action settlement and the allocated
$146 million loss on early extinguishment of debt. In addition, the rate was
adversely impacted by certain tax costs incurred in connection with the
Company's separation from Tyco and other adjustments to legacy income tax
liabilities.

    Pro forma diluted loss per share from continuing operations of ($2.23)
included the following items: $2.43 relating to Covidien's portion of the Tyco
International class action settlement, $0.31 for the loss on early
extinguishment of debt, $0.12 for other tax matters that impacted our
effective tax rate, $0.04 for in-process R&D and $0.01 for restructuring.
Excluding these items, pro forma diluted earnings per share from continuing
operations was $0.67.

    "Our third-quarter operating results were in line with our expectations,
as we successfully managed our separation from Tyco International while
continuing to deliver sales and results consistent with our plans," said
President and Chief Executive Officer Richard J. Meelia. "Third-quarter sales
growth was paced by a very good performance by our Medical Devices and
Pharmaceutical Products segments, aided by new products, acquisitions and
partial recovery from last year's product-related issues. We again achieved an
excellent performance in our International markets, reflecting the incremental
investments we made over the last three years to augment the sales force and
expand geographically.

    "On an adjusted basis, our operating margin was right on plan, driven by
a significant improvement in gross margin. As expected, we stepped up
investments in selling and marketing and increased R&D spending, which
negatively affected our earnings, but improved top-line performance. These
investments will enable us to further broaden our selling presence and
accelerate sales and earnings growth in the future," Mr. Meelia said.

    "Moving forward as an independent company, we are poised to deliver on
our growth targets and strengthen our position as a global leader in the
healthcare industry," Mr. Meelia added.

    Results by business segment follow.

    Medical Devices sales increased 9% in the quarter to $1.6 billion from
$1.5 billion in the previous year. Sales growth was driven by new products and
acquisitions. Favorable foreign exchange contributed 3 percentage points to
the sales growth rate and benefited all product groups in the segment. Sales
of Surgical Devices climbed at a double-digit pace, led by laparoscopic
instruments, a strong performance in Europe and Asia-Pacific and the benefit
of the 2006 Confluent acquisition. Sales of Energy-based Devices also
increased at a double-digit rate, with strong growth for vessel sealing in
both the United States and Europe. Respiratory and Monitoring Solutions sales
rose above those of last year, due to a good performance in International
markets and the acquisition of Airox. Sales of Patient Care and Safety
Products were above those of a year ago, led by higher sales of pre-filled
syringes and vascular therapy products.

    During the quarter, the Company announced the acquisition of AbsorbaTack
absorbable tack technology from Sorbx. AbsorbaTack, used in hernia repair
procedures, is expected to expand our Surgical Devices product portfolio and
leverage our global capabilities.

    Imaging Solutions sales rose 5% to $238 million, compared with $227
million in the prior year's third quarter. Favorable foreign exchange
contributed 2 percentage points to the sales growth rate. Sales of
Radiopharmaceuticals were well above those of last year, due to higher sales
of cardiology and oncology products, as well as increased generator volume.
The generator sales gain was aided by comparison to the year-ago period, when
recall issues restrained sales. Sales of Contrast Agents and Contrast Delivery
Systems were about even with a year ago. Growth in Contrast Delivery Systems
was countered by a small decline in sales of Contrast Agents, as higher
Contrast Agent unit volume was more than offset by significant pricing
declines in the quarter.

    Pharmaceutical Products sales increased 8% to $333 million from $307
million in the third quarter of last year. Sales growth was paced by
double-digit gains in active pharmaceutical ingredients (API), coupled with
higher sales of dosage pharmaceuticals and specialty chemicals. The API sales
increase was attributable to growth in narcotic products and bulk
acetaminophen. In specialty chemicals, the strong quarterly sales advance was
due to pharmaceutical and laboratory chemicals.

    Medical Supplies sales decreased 3% to $247 million from $255 million in
the third quarter of the previous year. The decline was primarily due to lower
sales of Original Equipment Manufacturer (OEM) products, including needles and
pre-filled syringes.

    Retail Products sales of $178 million in the quarter were 18% below last
year's $217 million. The sales decline resulted primarily from lower infant
care volume, attributable to the planned withdrawal from several low-margin,
private-label contracts.

    OUTLOOK

    Consistent with prior guidance, the Company estimates sales growth for
the 2007 fiscal year will be in the 4% - 6% range, including the impact of
foreign exchange. Sales are expected to increase mid-single digits in the
Medical Devices segment and high single digits in both the Imaging Solutions
and Pharmaceutical Products segments. The Company expects sales in Medical
Supplies to be flat or slightly below a year ago and sales of Retail Products
to be well below last year. The operating margin for fiscal 2007 is expected
to be in the 20 - 21% range, excluding the allocated class action settlement,
in-process R&D and restructuring expenses.

    For fiscal 2008, the Company continues to expect sales to be up 3% - 5%,
excluding the impact of foreign exchange. Operating margin is estimated to be
in the 19% - 20% range, excluding any in-process R&D and restructuring
expenses. Consistent with prior guidance, we anticipate the effective tax rate
will be in the 30% - 32% range for fiscal 2008.

    ABOUT COVIDIEN LTD.

    Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers value
through clinical leadership and excellence. Covidien manufactures, distributes
and services a diverse range of industry-leading product lines, including
Surgical Devices, Energy-based Devices, Respiratory and Monitoring Solutions,
Patient Care and Safety Products, Imaging Solutions, Pharmaceutical Products,
Medical Supplies and Retail Products. With 2006 revenue of nearly $10 billion,
Covidien has more than 43,000 employees worldwide in 57 countries, and its
products are sold in over 130 countries. For additional information, please
visit our website, www.covidien.com.

    CONFERENCE CALL AND WEBCAST

    The Company will hold a conference call for investors today, beginning at
8:30 a.m. EDT. This call can be accessed three ways:

    --  Web - Go to Covidien's website at http://www.covidien.com. A replay
of the call will be available through August 16 at the same website.

    --  Telephone - The dial-in number for participants in the United States
is (866)-831-6247. For participants outside the United States, the dial-in
number is (617)-213-8856. The access code for both numbers is 42577931.

    --  Audio replay - The conference call will be available for replay,
beginning at noon EDT on August 9, 2007, and ending at 11:59 p.m. on August
16, 2007. The dial-in number for participants in the United States is
(888)-286-8010. For participants outside the United States, the replay dial-in
number is (617)-801-6888. The replay access code for all callers is 29498804.

    NON-GAAP FINANCIAL MEASURES

    This press release contains financial measures, including adjusted
operating income, adjusted earnings per share and adjusted operating margin,
that are considered "non-GAAP" financial measures under applicable Securities
& Exchange Commission rules and regulations. These non-GAAP financial measures
should be considered supplemental to and not a substitute for financial
information prepared in accordance with generally accepted accounting
principles. The definition of these non-GAAP measures may differ from
similarly titled measures used by others.

    The non-GAAP financial measures used in this press release adjust for
specified items that can be highly variable or difficult to predict. The
Company generally uses these non-GAAP financial measures to facilitate
management's financial and operational decision-making, including evaluation
of Covidien's historical operating results, comparison to competitors'
operating results and to determine management incentive compensation. These
non-GAAP financial measures reflect an additional way of viewing aspects of
the Company's operations that, when viewed with GAAP results and the
reconciliations to corresponding GAAP financial measures, may provide a more
complete understanding of factors and trends affecting Covidien's business.

    Because non-GAAP financial measures exclude the effect of items that will
increase or decrease the Company's reported results of operations, management
strongly encourages investors to review the Company's consolidated financial
statements and publicly filed reports in their entirety. A reconciliation of
the non-GAAP financial measures to the most directly comparable GAAP financial
measures is included in the tables accompanying this release.

    The Company presents its operating margin forecast before special items
to give investors a perspective on the expected underlying business results.
Because the Company cannot predict the amount and timing of such items and the
associated charges or gains that will be recorded in the Company's financial
statements, it is difficult to include the impact of those items in the
forecast.

    BASIS OF PRESENTATION

    The accompanying Financial Statements reflect the consolidated operations
of Covidien Ltd. and its subsidiaries as an independent publicly-traded
company as of June 29, 2007, and a combined reporting entity comprising the
assets and liabilities used in managing and operating Tyco International's
healthcare businesses, including Covidien Ltd., prior to June 29, 2007. The
Company's Financial Statements for periods prior to June 29, 2007 may not be
indicative of its future performance and do not necessarily reflect what its
combined results of operations, financial condition and cash flows would have
been had it operated as an independent, publicly-traded company during the
periods presented, including changes in the Company's capitalization as a
result of the separation from Tyco International.

    FORWARD-LOOKING STATEMENTS

    This release contains certain "forward-looking statements" within the
meaning of the United States Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations and are
subject to risks, uncertainty and changes in circumstances, which may cause
actual results, performance or achievements to differ materially from
anticipated results, performance or achievements. All statements contained
herein that are not clearly historical in nature are forward-looking and the
words "anticipate," "believe," "expect," "estimate," "plan," and similar
expressions are generally intended to identify forward-looking statements.

    The forward-looking statements in this release may include statements
addressing the following subjects: future financial condition and operating
results. Economic, business, competitive and/or regulatory factors affecting
Covidien's business are examples of factors, among others, that could cause
actual results to differ materially from those described in the
forward-looking statements. Covidien is under no obligation to (and expressly
disclaims any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
More detailed information about these and other factors is set forth in the
Information Statement filed as Exhibit 99.1 to the Covidien Ltd. Form 8-K
filing on June 8, 2007.

    
                                Covidien Ltd.
                Combined Statements of Operations (unaudited)
                Quarters Ended June 29, 2007 and June 30, 2006
                     (in millions, except per share data)

                                               Quarters Ended
                                  ----------------------------------------
                                  June 29, Percent of June 30,  Percent of
                                    2007   Net Sales    2006    Net Sales
                                  ------------------- --------------------

    Net sales                     $  2,579     100.0%    $2,464     100.0%
    Cost of products sold            1,337       51.8     1,306       53.0
                                  --------            ---------
        Gross profit                 1,242       48.2     1,158       47.0

    Selling, general and
     administrative expenses           662       25.7       536       21.8
    Research and development
     expenses                           68        2.6        64        2.6
    Class action settlement, net
     of insurance recovery           1,207       46.8        --         --
    Restructuring charges                5        0.2        --         --
    Loss on divestiture                 --         --         1         --
    In-process research and
     development charge                 30        1.2        --         --
                                  --------            ---------
        Operating (loss) income      (730)     (28.3)       557       22.6

    Interest expense                    46        1.8        40        1.6
    Interest income                    (9)      (0.3)       (6)      (0.2)
    Other expense, net                 156        6.0         1         --
                                  --------            ---------
        (Loss) income from
         continuing operations
         before income taxes         (923)     (35.8)       522       21.2

    Income taxes                       184        7.1       135        5.5
                                  --------            ---------
        (Loss) income from
         continuing operations     (1,107)     (42.9)       387       15.7

    Loss from discontinued
     operations, net of income
     taxes                               1         --        26        1.1
                                  --------            ---------
        Net (loss) income         $(1,108)     (43.0)    $  361       14.7
                                  --------            ---------

    Pro forma basic and diluted
     earnings per share (1):
       (Loss) income from
        continuing operations     $ (2.23)               $ 0.78
       Loss from discontinued
        operations                      --                 0.05
       Net (loss) income            (2.23)                 0.73

    Pro forma basic and diluted
     shares outstanding (1)            497                  497


    (1) Following the separation from Tyco International, Covidien had 497
     million common shares outstanding. This share amount was used to
     calculate pro forma earnings per share for all periods presented. The
     same number of shares was used to calculate diluted earnings per
     share and basic earnings per share because no common shares of
     Covidien were publicly available on or before June 29, 2007, and no
     Covidien restricted shares or share options were outstanding prior to
     the Separation.
    

    
                                Covidien Ltd.
                Combined Statements of Operations (unaudited)
              Nine Months Ended June 29, 2007 and June 30, 2006
                     (in millions, except per share data)

                                             Nine Months Ended
                                 -----------------------------------------
                                 June 29,  Percent of June 30,  Percent of
                                   2007    Net Sales    2006    Net Sales
                                 -------------------- --------------------

    Net sales                      $ 7,569     100.0%    $7,166     100.0%
    Cost of products sold            3,979       52.6     3,820       53.3
                                 ---------            ---------
        Gross profit                 3,590       47.4     3,346       46.7

    Selling, general and
     administrative expenses         1,840       24.3     1,561       21.8
    Research and development
     expenses                          197        2.6       194        2.7
    Class action settlement, net
     of insurance recovery           1,207       15.9        --         --
    Restructuring charges               26        0.3        --         --
    (Gain) on divestiture               --         --      (45)      (0.6)
    In-process research and
     development charges                38        0.5         3         --
                                 ---------            ---------
        Operating income               282        3.7     1,633       22.8

    Interest expense                   125        1.7       131        1.8
    Interest income                   (28)      (0.4)      (23)      (0.3)
    Other expense, net                 150        2.0         6        0.1
                                 ---------            ---------
        Income from continuing
         operations before
         income taxes                   35        0.5     1,519       21.2

    Income taxes                       406        5.4       384        5.4
                                 ---------            ---------
        (Loss) income from
         continuing operations       (371)      (4.9)     1,135       15.8

    Loss from discontinued
     operations, net of income
     taxes                               5        0.1       320        4.5
                                 ---------            ---------
        Net (loss) income          $ (376)      (5.0)    $  815       11.4
                                 ---------            ---------

    Pro forma basic and diluted
     earnings per share (1):
       (Loss) income from
        continuing operations      $(0.75)               $ 2.28
       Loss from discontinued
        operations                    0.01                 0.64
       Net (loss) income            (0.76)                 1.64

    Pro forma basic and diluted
     shares outstanding (1)            497                  497


    (1) Following the separation from Tyco International, Covidien had 497
     million common shares outstanding. This share amount was used to
     calculate pro forma earnings per share for all periods presented. The
     same number of shares was used to calculate diluted earnings per
     share and basic earnings per share because no common shares of
     Covidien were publicly available on or before June 29, 2007, and no
     Covidien restricted shares or share options were outstanding prior to
     the Separation.
    

    
                                Covidien Ltd.
                  Segment and Geographical Sales (unaudited)
        Quarters and Nine Months Ended June 29, 2007 and June 30, 2006
                                (in millions)


                                                    Quarters Ended
                                            ------------------------------
                                            June 29,  June 30,  Percentage
                                              2007      2006      Change
                                            --------- --------- ----------

    Segment net sales:
       Medical Devices                         $1,583    $1,458       8.6%
       Imaging Solutions                          238       227        4.8
       Pharmaceutical Products                    333       307        8.5
       Medical Supplies                           247       255      (3.1)
       Retail Products                            178       217     (18.0)
                                            --------- ---------
                                               $2,579    $2,464        4.7
                                            --------- ---------



                                                    Quarters Ended
                                            ------------------------------
                                            June 29,  June 30,  Percentage
                                               2007      2006     Change
                                            --------- --------- ----------

    Geographical net sales:
       U.S.                                    $1,547    $1,524       1.5%
       Other Americas                             129       113       14.2
       Europe                                     650       574       13.2
       Japan                                      139       144      (3.5)
       Asia-Pacific                               114       109        4.6
                                            --------- ---------
                                               $2,579    $2,464        4.7
                                            --------- ---------


                                                  Nine Months Ended
                                            ------------------------------
                                            June 29,  June 30,  Percentage
                                              2007      2006      Change
                                            --------- --------- ----------

    Segment net sales:
       Medical Devices                         $4,553    $4,238       7.4%
       Imaging Solutions                          690       642        7.5
       Pharmaceutical Products                  1,003       905       10.8
       Medical Supplies                           743       739        0.5
       Retail Products                            580       642      (9.7)
                                            --------- ---------
                                               $7,569    $7,166        5.6
                                            --------- ---------



                                                  Nine Months Ended
                                            ------------------------------
                                            June 29,  June 30,  Percentage
                                               2007     2006      Change
                                            --------- --------- ----------

    Geographical net sales:
       U.S.                                    $4,605    $4,482       2.7%
       Other Americas                             354       326        8.6
       Europe                                   1,856     1,636       13.4
       Japan                                      420       421      (0.2)
       Asia-Pacific                               334       301       11.0
                                            --------- ---------
                                               $7,569    $7,166        5.6
                                            --------- ---------
    

    
                                Covidien Ltd.
                     Non-GAAP Reconciliations (unaudited)
                 Quarter and Nine Months Ended June 29, 2007
                     (in millions, except per share data)


                                    Quarter Ended June 29, 2007
                          ------------------------------------------------
                                       (Loss)                  Pro forma
                                       income                  basic and
                                        from                   diluted
                                     continuing    (Loss)       (loss)
                                     operations    income    earnings per
                          Operating    before       from      share from
                            (loss)     income    continuing   continuing
                            income      taxes    operations   operations
                          ---------- ----------- ----------- -------------

    GAAP                      $(730)      $(923)    $(1,107)       $(2.23)
    Adjustments:
       Class action
        settlement, net
        of insurance
        recovery (1)           1,207       1,207       1,207          2.43
       Restructuring
        charges (2)                5           5           3          0.01
       In-process
        research and
        development
        charge (3)                30          30          22          0.04
       Loss on the early
        extinguishment of
        debt (4)                  --         155         152          0.31
       Tax matters (5)            --          --          58          0.12
                          ---------- ----------- -----------
    As adjusted               $  512      $  474    $    335          0.67
                          ---------- ----------- -----------


    (1) We were allocated a net charge of $1,207 million from Tyco
     International for our portion of Tyco International's class action
     settlement. This amount is comprised of our portion of the class
     action settlement of $1,249 million, net of our portion of the
     related insurance recovery of $42 million.

    (2) Restructuring charges of $5 million related primarily to severance
     costs within our Medical Devices segment.

    (3) Our Medical Devices segment recorded an in-process research and
     development charge of $30 million in connection with the acquisition
     of intellectual property from Sorbx, LLC.

    (4) We recorded a loss on the early extinguishment of debt of $155
     million, of which $146 million was allocated by Tyco International.
     The loss on the early extinguishment of debt was included in "Other
     expense, net" in our Combined Statement of Operations.

    (5) Our tax rate was negatively impacted by $58 million of certain tax
     costs incurred in connection with our separation from Tyco
     International and other adjustments to legacy income tax liabilities.

                                  Nine Months Ended June 29, 2007
                          ------------------------------------------------
                                                              Pro forma
                                                               basic and
                                     Income from                diluted
                                      continuing   (Loss)       (loss)
                                      operations   income     earnings per
                                       before       from      share from
                          Operating    income     continuing  continuing
                            income      taxes     operations   operations
                          ---------- ----------- ----------- -------------

    GAAP                      $  282      $   35    $  (371)       $(0.75)
    Adjustments:
       Class action
        settlement, net
        of insurance
        recovery (1)           1,207       1,207       1,207          2.43
       Restructuring
        charges (2)               26          26          17          0.03
       In-process
        research and
        development
        charges (3)               38          38          30          0.06
       Loss on the early
        extinguishment of
        debt (4)                  --         155         152          0.31
       Tax matters (5)            --          --          12          0.02
                          ---------- ----------- -----------
    As adjusted               $1,553      $1,461    $  1,047          2.11
                          ---------- ----------- -----------


    (1) We were allocated a net charge of $1,207 million from Tyco
     International for our portion of Tyco International's class action
     settlement. This amount is comprised of our portion of the class
     action settlement of $1,249 million, net of our portion of the
     related insurance recovery of $42 million.

    (2) Restructuring charges of $26 million related primarily to
     severance costs within our Medical Devices segment.

    (3) Our Medical Devices segment recorded an in-process research and
     development charge of $30 million in connection with the acquisition
     of intellectual property from Sorbx, LLC. In addition, our Medical
     Devices segment recorded an in-process research and development
     charge of $8 million in connection with the acquisition of the
     remaining outstanding shares of Airox S.A.

    (4) We recorded a loss on the early extinguishment of debt of $155
     million, of which $146 million was allocated by Tyco International.
     The loss on the early extinguishment of debt was included in "Other
     expense, net" in our Combined Statement of Operations.

    (5) Our tax rate was negatively impacted by $12 million, which
     consists of certain tax costs incurred in connection with our
     separation from Tyco International and other adjustments to legacy
     income tax liabilities, partially offset by the release of deferred
     tax valuation allowances related to changes in a non-U.S. tax law.
    

    
                                Covidien Ltd.
                     Non-GAAP Reconciliations (unaudited)
                 Quarter and Nine Months Ended June 30, 2006
                     (in millions, except per share data)


                                      Quarter Ended June 30, 2006
                             ---------------------------------------------

                                                               Pro forma
                                                                basic and
                                       Income from               diluted
                                        continuing              earnings
                                        operations              per share
                                         before    Income from    from
                             Operating   income     continuing  continuing
                               income     taxes     operations  operations
                             --------- ----------- ----------- -----------

    GAAP                          $557        $522        $387       $0.78
    Adjustments:
       Loss on divestiture
        (1)                          1           1           1          --
       Tax matters                  --          --           4        0.01
                             --------- ----------- -----------
    As adjusted                   $558        $523        $392        0.79
                             --------- ----------- -----------


    (1) Loss of $1 million is related to the sale of the Radionics product
     line within the Medical Devices segment.

                                    Nine Months Ended June 30, 2006
                             ---------------------------------------------

                                                               Pro forma
                                                                basic and
                                       Income from               diluted
                                        continuing              earnings
                                        operations              per share
                                         before    Income from    from
                             Operating   income     continuing  continuing
                               income     taxes     operations  operations
                             --------- ----------- ----------- -----------

    GAAP                        $1,633      $1,519      $1,135       $2.28
    Adjustments:
       (Gain) on divestiture
        (1)                       (45)        (45)        (36)      (0.07)
       In-process research
        and development
        charge (2)                   3           3           3        0.01
       Tax matters                  --          --           7        0.01
                             --------- ----------- -----------
    As adjusted                 $1,591      $1,477      $1,109        2.23
                             --------- ----------- -----------


    (1) (Gain) of $45 million is related to the sale of the Radionics
     product line within the Medical Devices segment.

    (2) The Medical Devices segment recorded in-process research and
     development charges of $3 million in connection with the acquisition
     of over 90% of Floreane Medical Implants, S.A.
    




For further information:

For further information: Covidien Ltd. Eric Kraus, 508-261-8305 Senior
Vice President Corporate Communications eric.kraus@covidien.com or Coleman
Lannum, CFA, 508-452-4343 Vice President Investor Relations
cole.lannum@covidien.com or Bruce Farmer, 508-452-4372 Director Financial
Communications bruce.farmer@covidien.com or Wayde McMillan, 508-452-4387
Director Investor Relations wayde.mcmillan@covidien.com

Organization Profile

COVIDIEN

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890